Fewer than half of women who tested positive for HPV with negative cytological findings returned for a surveillance co-test within 1 year as recommended, yet more than half of those who received ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.